The U.S. FDA granted accelerated approval for the Biologics License Application for Axogen Inc.'s Avance, an acellular nerve ...

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow ...

On Dec. 2, 2025, the FDA released draft guidance that could reduce the use of nonhuman primates (NHPs) in preclinical testing ...

Disorganization resulting from last-minute changes to voting questions involving new recommendations for hepatitis B virus vaccines created a moment of déjà vu Dec. 4 when the CDC’s Advisory Committee ...

After raising more than twice as much as expected in its March IPO, Kestra Medical Technologies Inc. appears poised to repeat ...

Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically ...

Ireland’s life sciences and health tech companies raised a record-breaking €491.3 million ($572.9 million) in venture capital ...

Shares of San Diego-based Capricor Therapeutics Inc. (NASDAQ: CAPR) closed Dec. 3 at $29.96, up $23.60, or 371%, as investors ...

Vectory Therapeutics BV has obtained IND clearance from the FDA for a phase I/II trial (PIONEER-ALS) of VTX-002, a ...

Abion Inc. has presented data for ABN-202, a hyperglycosylated interferon (IFN) β mutein fused to a monoclonal antibody ...

Neuroblastoma is a pediatric extracranial solid tumor arising from the sympathetic nervous system. Disialoganglioside ...

Proving its latest addition to the Farapulse pulsed field ablation (PFA) platform is no turkey, Boston Scientific Corp.'s ...